Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AZD7009, no generic name available · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| AZD7009, no generic name available | DRUG | - |
Inclusion Criteria: * Clinical indication for cardioversion of Atrial Fibrillation. Effective oral anticoagulation according to local routines or a TEE without any finding of intracardial thrombus or signs of thrombogenecity Exclusion Criteria: * Clinically significant sinus and/or AV node dysfun...
Top 4 of 13 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Regeneron Pharmaceuticals, Inc. | REGN | 2 | PHASE3 | REGN7508, REGN9933 |
| Johnson & Johnson | JNJ | 2 | PHASE3 | Milvexian |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE2 | PKN605 |
| Milestone Pharmaceuticals, Inc. | MIST | 1 | PHASE3 | Etripamil |
AZD7009 is an investigational small molecule developed for the treatment of atrial fibrillation, a common heart rhythm disorder. It was studied in a Phase 2 clinical trial that enrolled 160 patients across eight European countries. AZD7009 has not been approved for any indication and remains an experimental therapy.
AZD7009 targets the cardiac ion channels SCN5A and KCNH2. It acts as a blocker of these channels, which are involved in regulating electrical activity in the heart. This dual-channel blocking profile was designed to help restore and maintain normal sinus rhythm in patients with atrial fibrillation.
AZD7009 is being developed by AstraZeneca PLC, which trades on the Nasdaq under the ticker AZN. AstraZeneca sponsored the Phase 2 clinical trial evaluating the drug in atrial fibrillation. The compound is an investigational asset within AstraZeneca's cardiovascular pipeline.
AZD7009 is in Phase 2 clinical development. It has completed one Phase 2 trial in atrial fibrillation with 160 patients enrolled. The trial was randomized and double-blind. AZD7009 is not FDA approved and remains an investigational drug that has not advanced beyond mid-stage clinical testing.
AZD7009 has been studied in one completed Phase 2 trial, NCT00255281, titled Efficacy and Safety of AZD7009 in the Treatment of Atrial Fibrillation. The trial enrolled 160 patients aged 18 and older across Denmark, Finland, Germany, Hungary, Netherlands, Norway, Poland, and Sweden. No active trials are currently listed.